The Urologic Impact of Long-Term Finasteride-1 Mg Use for Androgenic Alopecia: A Matched-Cohort Database Analysis

    April 2025 in “ The Journal of Urology
    Perry Xu, Amir Patel, Ariel Roane, C. Parker Gibbs, Danit Mechlovich, Remi Bucko, Laura Stock, Amy E. Krambeck
    TLDR Long-term finasteride use may lower prostate cancer risk but increase the need for erectile dysfunction medication.
    The study analyzed the urologic impact of long-term finasteride-1 mg (F1) use in 3,470 men with androgenic alopecia, compared to a matched cohort of 3,470 men not using F1. Results showed that F1 users were more likely to be prescribed PDE5 inhibitors and received them approximately 230 days earlier than non-users. There were no significant differences in benign prostatic hyperplasia diagnosis or treatment rates between the groups. However, F1 use was associated with lower rates of elevated PSA and prostate cancer diagnoses. The study suggests that while F1 may influence certain urologic outcomes, further research is needed to fully understand its long-term effects.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 1000+ results

    Similar Research

    5 / 1000+ results